Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Orally available, flexible and novel, Janus kinase inhibitors are poised to trigger major treatment shakeups in at least two disease spaces. Two drugs at the head of the JAK pack are close to coming of age – Pfizer Inc.’s tofacitinib and Incyte Corp.’s ‘18424 – and hopes are high, though questions remain about selectivity, long-term side effects and just how far the class can go.

You may also be interested in...



JAK Inhibitors Start To Come Of Age In Rheumatoid Arthritis

Oral class has gotten off to slow start, but data for range of JAK inhibitors – including Lilly’s once-daily baricitinib – presented at American College of Rheumatology meeting are encouraging.

With Remicade Biosimilar On The Rise, J&J Adds Astellas’ JAK2 To Pipeline

The unknowns of JAK inhibitors still offer substantial promise, and Pfizer will likely be the first test subject in the RA space.

With Remicade Biosimilar On The Rise, J&J Adds Astellas’ JAK2 To Pipeline

The unknowns of JAK inhibitors still offer substantial promise, and Pfizer will likely be the first test subject in the RA space.

Related Content

Topics

UsernamePublicRestriction

Register

PS004672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel